Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis.
作者信息
Golwala Harsh, Bajaj Navkaranbir Singh, Arora Garima, Arora Pankaj
机构信息
From Brigham and Women's Heart and Vascular Institute, Boston, MA (H.G., N.S.B.); Division of Cardiovascular Disease, Department of Medicine, University of Alabama, Birmingham (G.A., P.A.).
出版信息
Circulation. 2017 Jan 10;135(2):201-203. doi: 10.1161/CIRCULATIONAHA.116.026056. Epub 2016 Dec 19.
Abstract
摘要
相似文献
1
Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis.
Circulation. 2017 Jan 10;135(2):201-203. doi: 10.1161/CIRCULATIONAHA.116.026056. Epub 2016 Dec 19.
2
Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
Cardiovasc Ther. 2017 Jun;35(3). doi: 10.1111/1755-5922.12253.
3
Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy.
Angiology. 2018 Apr;69(4):297-302. doi: 10.1177/0003319717710851. Epub 2017 May 30.
4
Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis.
JAMA Cardiol. 2017 Jun 1;2(6):685-688. doi: 10.1001/jamacardio.2017.0630.
5
Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
J Cardiovasc Electrophysiol. 2017 May;28(5):538-543. doi: 10.1111/jce.13192. Epub 2017 Mar 30.
6
Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):179-86. doi: 10.1161/CIRCOUTCOMES.114.001306. Epub 2015 Feb 10.
7
Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis.
Heart. 2018 Jan;104(2):144-150. doi: 10.1136/heartjnl-2016-310850. Epub 2017 Oct 6.
8
Letter by Barakat et al Regarding Article, "Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis".
Circulation. 2017 Jun 20;135(25):e1196-e1197. doi: 10.1161/CIRCULATIONAHA.116.027106.
9
Letter by Nery et al Regarding Article, "Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis".
Circulation. 2017 Jun 20;135(25):e1198-e1199. doi: 10.1161/CIRCULATIONAHA.117.027389.
10
Response by Golwala et al to Letter Regarding Article, "Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis".
Circulation. 2017 Jun 20;135(25):e1200-e1202. doi: 10.1161/CIRCULATIONAHA.117.028200.
引用本文的文献
1
JCS/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias.
J Arrhythm. 2025 Jun 16;41(3):e70033. doi: 10.1002/joa3.70033. eCollection 2025 Jun.
2
Radiomic Cardiac MRI Signatures for Predicting Ventricular Arrhythmias in Patients With Nonischemic Dilated Cardiomyopathy.
JACC Adv. 2025 Apr;4(4):101684. doi: 10.1016/j.jacadv.2025.101684. Epub 2025 Mar 23.
3
Current and Future of Heart Failure Care in Asia.
Int J Heart Fail. 2024 Oct 25;6(4):141-148. doi: 10.36628/ijhf.2024.0033. eCollection 2024 Oct.
4
Enhancing patient acceptance of ICD implantation through structured shared decision making: conversation is key.
J Interv Card Electrophysiol. 2024 Dec;67(9):2077-2087. doi: 10.1007/s10840-024-01850-7. Epub 2024 Jul 13.
5
Multimodal explainable artificial intelligence identifies patients with non-ischaemic cardiomyopathy at risk of lethal ventricular arrhythmias.
Sci Rep. 2024 Jun 27;14(1):14889. doi: 10.1038/s41598-024-65357-x.
6
Implantable Cardioverter Defibrillator Tachycardia Therapies: Past, Present and Future Directions.
J Cardiovasc Dev Dis. 2024 Mar 20;11(3):92. doi: 10.3390/jcdd11030092.
7
An updated meta-analysis of cardiac resynchronization therapy with or without defibrillation in patients with nonischemic cardiomyopathy.
Front Cardiovasc Med. 2023 Jul 12;10:1078570. doi: 10.3389/fcvm.2023.1078570. eCollection 2023.
8
Age-stratified comparison of prognosis in cardiac resynchronization therapy with or without prophylactic defibrillator for nonischemic cardiomyopathy-a nationwide cohort study.
Europace. 2023 Jul 4;25(7). doi: 10.1093/europace/euad187.
9
Use of Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death in Asia.
JACC Asia. 2023 Apr 25;3(3):335-345. doi: 10.1016/j.jacasi.2023.02.004. eCollection 2023 Jun.
10
Sex differences in one-year recurrence and all-cause mortality following catheter ablation of ventricular tachycardia in structural heart disease.
Front Cardiovasc Med. 2022 Dec 6;9:1061471. doi: 10.3389/fcvm.2022.1061471. eCollection 2022.
本文引用的文献
1
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure.
N Engl J Med. 2016 Sep 29;375(13):1221-30. doi: 10.1056/NEJMoa1608029. Epub 2016 Aug 27.
2
2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
Circulation. 2013 Jan 22;127(3):e283-352. doi: 10.1161/CIR.0b013e318276ce9b. Epub 2012 Dec 19.
3
Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials.
JAMA. 2004 Dec 15;292(23):2874-9. doi: 10.1001/jama.292.23.2874.
4
Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.
J Am Coll Cardiol. 2004 Dec 7;44(11):2166-72. doi: 10.1016/j.jacc.2004.08.054.
5
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.
N Engl J Med. 2000 Apr 13;342(15):1077-84. doi: 10.1056/NEJM200004133421502.
Zotero 插件